Try our beta test site
36 studies found for:    Open Studies | "Carcinoma, Basal Cell"
Show Display Options
Rank Status Study
21 Recruiting Randomized Pilot Study of Treatment for BCC Using the Multiplex 595/1064 nm Laser
Conditions: Nodular Basal Cell Carcinoma;   Superficial Basal Cell Carcinoma
Intervention: Device: 595/1064 multiplex laser
22 Recruiting Superficial Basal Cell Cancer's Photodynamic Therapy: Comparing Three Photosensitises: HAL and BF-200 ALA Versus MAL
Conditions: Neoplasms, Basal Cell;   Carcinoma, Basal Cell;   Photochemotherapy;   Photosensitizing Agents
Interventions: Drug: Hexylaminolevulinate cream;   Drug: Aminolevulinic Acid Nano Emulsion;   Drug: Methylaminolevulinate cream
23 Recruiting Phase II Study of Radiation Therapy and Vismodegib for Advanced Head/Neck Basal Cell Carcinoma
Conditions: Locally Advanced Basal Cell Carcinoma;   Skin Cancer;   Cutaneous Malignancy
Interventions: Drug: Vismodegib;   Radiation: Radiation therapy
24 Recruiting A Study of the Efficacy and Safety of ASN-002 in Adult Patients With Low-risk Nodular Basal Cell Carcinoma
Conditions: Basal Cell Nevus Syndrome;   Skin Neoplasm;   Nodular Basal Cell Carcinoma of Skin
Interventions: Biological: ASN-002;   Drug: 5-FU
25 Recruiting Safety and Efficacy of Oshadi D and Oshadi R in Basal Cell Carcinoma Patients Prior to Tumor Excision a Phase 2 Study
Condition: BCC
Intervention: Drug: Oshadi D & Oshadi R
26 Recruiting Reflectance Confocal Microscopy of Wounds During Moh's Surgery: Feasibility Testing of a Mosaicing Algorithm for Intraoperative Imaging of Cancer Margins
Conditions: Basal Cell Carcinoma;   Squamous Cell Carcinoma
Intervention:
27 Recruiting Electronic Brachytherapy for the Treatment of NMSC
Conditions: Basal Cell Carcinoma;   Squamous Cell Carcinoma
Intervention: Radiation: electronic brachytherapy
28 Recruiting Laser Assisted Drug Delivery in the Treatment of Superficial Non Melanoma Skin Cancer: a Randomized Controlled Trial
Conditions: Bowen's Disease;   Superficial Basal Cell Carcinoma
Interventions: Device: full ablative CO2 laser;   Device: fractional ablative CO2 laser;   Drug: MAL;   Device: LED lamp;   Drug: lidocaine hydrochloride 2% with epinephrine
29 Recruiting Confocal Reflectance Microscopy of Shave-Biopsy Sites on Skin in Vivo.
Conditions: Basal Cell Carcinoma;   Melanoma;   Squamous Cell Carcinoma;   Non-Malignant Skin Disorders
Intervention: Procedure: confocal microscopy in vivo
30 Recruiting Skin Cancer Screening Education Study
Conditions: Skin Tumors;   Melanoma;   Basal Cell Carcinoma;   Squamous Cell Carcinoma
Intervention: Other: Skin Cancer Screening Training
31 Recruiting Cancer Risk in Carriers of the Gene for Xeroderma Pigmentosum
Conditions: Xeroderma Pigmentosum;   Melanoma;   Squamous Cell Carcinoma;   Basal Cell Carcinoma;   Skin Cancer
Intervention:
32 Recruiting Spanish Registry of Mohs Surgery
Conditions: Skin Neoplasms;   Carcinoma, Basal Cell;   Carcinoma, Squamous Cell;   Dermatofibrosarcoma;   Melanoma;   Histiocytoma, Malignant Fibrous;   Neoplasms, Adnexal and Skin Appendage
Intervention: Procedure: Mohs surgery
33 Recruiting Tele-dermatology of Skin Cancer in a Cohort of Local Health Authority Employees in the Province of Bergamo
Conditions: Erysipelas;   Impetigo;   Herpes Zoster;   Molluscum Contagiosum;   Warts;   Tinea;   Melanoma;   Actinic Keratosis;   Basal Cell Carcinoma;   Squamous Cell Carcinoma
Interventions: Procedure: Screening;   Device: Tele-dermatology
34 Not yet recruiting Talimogene Laherparepvec and Nivolumab in Treating Patients With Refractory Lymphomas or Advanced or Refractory Non-melanoma Skin Cancers
Conditions: Adenoid Cystic Carcinoma;   Adnexal Carcinoma;   Apocrine Carcinoma;   Eccrine Porocarcinoma;   Extraocular Cutaneous Sebaceous Carcinoma;   Hidradenocarcinoma;   Keratoacanthoma;   Malignant Sweat Gland Neoplasm;   Merkel Cell Carcinoma;   Microcystic Adnexal Carcinoma;   NK-Cell Lymphoma, Unclassifiable;   Non-Melanomatous Lesion;   Paget Disease;   Papillary Adenocarcinoma;   Primary Cutaneous Mucinous Carcinoma;   Refractory Anaplastic Large Cell Lymphoma;   Refractory Cutaneous T-Cell Non-Hodgkin Lymphoma;   Refractory Mature T-Cell and NK-Cell Non-Hodgkin Lymphoma;   Refractory Mycosis Fungoides;   Refractory T-Cell Non-Hodgkin Lymphoma;   Sezary Syndrome;   Signet Ring Cell Carcinoma;   Skin Basal Cell Carcinoma;   Skin Basosquamous Cell Carcinoma;   Skin Squamous Cell Carcinoma;   Spiradenocarcinoma;   Squamous Cell Carcinoma of Unknown Primary Origin;   Stage III Skin Cancer;   Stage IV Skin Cancer;   Sweat Gland Carcinoma;   Trichilemmocarcinoma;   Vulvar Squamous Cell Carcinoma
Interventions: Other: Laboratory Biomarker Analysis;   Biological: Nivolumab;   Biological: Talimogene Laherparepvec
35 Not yet recruiting Familial Investigations of Childhood Cancer Predisposition
Conditions: Acute Leukemia;   Adenomatous Polyposis;   Adrenocortical Carcinoma;   AML;   BAP1 Tumor Predisposition Syndrome;   Carney Complex;   Choroid Plexus Carcinoma;   Constitutional Mismatch Repair Deficiency Syndrome;   Diamond-Blackfan Anemia;   DICER1 Syndrome;   Dyskeratosis Congenita;   Emberger Syndrome;   Familial Acute Myeloid Leukaemia;   Familial Adenomatous Polyposis;   Fanconi Anemia;   Familial Cancer;   Familial Wilms Tumor;   Familial Neuroblastoma;   GIST;   Hereditary Breast and Ovarian Cancer;   Hereditary Paraganglioma-Pheochromocytoma Syndrome;   Hodgkin Lymphoma;   Juvenile Polyposis;   Li-Fraumeni Syndrome;   Lynch Syndrome;   MDS;   Melanoma Syndrome;   Multiple Endocrine Neoplasia Type 1;   Multiple Endocrine Neoplasia Type 2;   Neuroblastoma;   Neurofibromatosis Type 1;   Neurofibromatosis Type II;   Nevoid Basal Cell Carcinoma Syndrome;   Non Hodgkin Lymphoma;   Noonan Syndrome and Other Rasopathy;   Overgrowth Syndromes;   Pancreatic Cancer;   Peutz-Jeghers Syndrome;   Pheochromocytoma/Paraganglioma;   PTEN Hamartoma Tumor Syndrome;   Retinoblastoma;   Rhabdoid Tumor Predisposition Syndrome;   Rhabdomyosarcoma;   Rothmund-Thomson Syndrome;   Tuberous Sclerosis;   Von Hippel-Lindau Disease
Intervention:
36 Recruiting 18F FPPRGD2 PET/CT or PET/MRI in Predicting Early Response in Patients With Cancer Receiving Anti-Angiogenesis Therapy
Conditions: Adult Giant Cell Glioblastoma;   Adult Glioblastoma;   Adult Gliosarcoma;   Male Breast Cancer;   Metastatic Squamous Neck Cancer With Occult Primary Squamous Cell Carcinoma;   Recurrent Adenoid Cystic Carcinoma of the Oral Cavity;   Recurrent Adult Brain Tumor;   Recurrent Basal Cell Carcinoma of the Lip;   Recurrent Breast Cancer;   Recurrent Colon Cancer;   Recurrent Esthesioneuroblastoma of the Paranasal Sinus and Nasal Cavity;   Recurrent Hypopharyngeal Cancer;   Recurrent Inverted Papilloma of the Paranasal Sinus and Nasal Cavity;   Recurrent Laryngeal Cancer;   Recurrent Lip and Oral Cavity Cancer;   Recurrent Lymphoepithelioma of the Nasopharynx;   Recurrent Lymphoepithelioma of the Oropharynx;   Recurrent Metastatic Squamous Neck Cancer With Occult Primary;   Recurrent Midline Lethal Granuloma of the Paranasal Sinus and Nasal Cavity;   Recurrent Mucoepidermoid Carcinoma of the Oral Cavity;   Recurrent Nasopharyngeal Cancer;   Recurrent Non-small Cell Lung Cancer;   Recurrent Oropharyngeal Cancer;   Recurrent Pancreatic Cancer;   Recurrent Paranasal Sinus and Nasal Cavity Cancer;   Recurrent Rectal Cancer;   Recurrent Renal Cell Cancer;   Recurrent Salivary Gland Cancer;   Stage IIIA Breast Cancer;   Stage IIIA Non-small Cell Lung Cancer;   Stage IIIB Breast Cancer;   Stage IIIB Non-small Cell Lung Cancer;   Stage IIIC Breast Cancer;   Stage IV Breast Cancer;   Stage IV Non-small Cell Lung Cancer;   Stage IV Pancreatic Cancer;   Stage IV Renal Cell Cancer;   Stage IVA Colon Cancer;   Stage IVA Rectal Cancer;   Stage IVA Salivary Gland Cancer;   Stage IVB Colon Cancer;   Stage IVB Salivary Gland Cancer;   Stage IVC Salivary Gland Cancer;   Tongue Cancer;   Unspecified Adult Solid Tumor, Protocol Specific
Interventions: Radiation: fludeoxyglucose F 18;   Radiation: 2-fluoropropionyl-labeled pegylated dimeric RGD peptide;   Procedure: positron emission tomography;   Procedure: computed tomography;   Other: laboratory biomarker analysis

First Page    Show previous page of results Previous Page (1-20) Studies Shown (21-36) Next Page   
Study has passed its completion date and status has not been verified in more than two years.